Identification | Back Directory | [Name]
Beludavimab | [CAS]
2423016-74-2 | [Synonyms]
Beludavimab Research Grade Beludavimab Research Grade Beludavimab (DVV00309) |
Hazard Information | Back Directory | [Uses]
Beludavimab (BMS 4182137; VIR 7832) is a monoclonal antibody targeting the spike glycoprotein of SARS-CoV-2. Beludavimab binds to recombinant spike protein receptor-binding domain (S-RBD) with an EC50 value of 14.9 ng/mL and a Kd of 0.21 nM[1]. | [References]
[1] Andrea L. Cathcart, et al. The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2. bioRxiv. April 01, 2022. |
|
Company Name: |
Biolab Reagents
|
Tel: |
18108604356 |
Website: |
www.biolabreagent.com/ |
Company Name: |
Cell Sciences
|
Tel: |
9785721070 |
Website: |
www.cellsciences.com |
Company Name: |
Biorbyt Ltd.
|
Tel: |
+44 (0)1223 859 353 |
Website: |
http://www.biorbyt.com |
|